ClinicalTrials.Veeva

Menu

Effect of Phenazopyridine on Prolapse Surgery Voiding Trials (EPOV)

U

University of Massachusetts, Worcester

Status and phase

Completed
Phase 3

Conditions

Urinary Retention Postoperative

Treatments

Drug: Phenazopyridine

Study type

Interventional

Funder types

Other

Identifiers

NCT03065075
H00012082

Details and patient eligibility

About

To determine if phenazopyridine reduces the rate of postoperative urinary retention after pelvic organ prolapse surgery.

Full description

Several tools can be used to evaluate for ureteral patency during urogynecologic procedures. Typically, surgeons use urine dyes such as methylene blue, indigotindisulfonate sodium, or phenazopyridine, with the latter being restricted to oral administration. However in June 2014, the two U.S. manufacturers of indigotindisulfonate sodium stopped producing the medication and there is no prospect that it will be returning soon. Phenazopyridine is an over-the-counter medication (Azo-Gesic, Baridium, Urinary Pain Relief) that has been used safely for decades as a bladder analgesic and taints the urine orange.

Over the past few months, increasing evidence suggests that phenazopyridine may reduce transient postoperative urinary retention. Transient urinary retention is common after urogynecologic surgery and is assessed postoperatively by performing a void trial (VT) prior to discharge. In a study designed to determine the time from administration of oral phenazopyridine to visualize dye from the ureters, Propst et al incidentally found that 38% of patients (19 of 49) failed postoperative VTs without phenazopyridine, but only 19% (9 of 47) failed with phenazopyridine, p=0.04. Most recently, a study by Duenas-Garcia et al designed to examine local anesthetics and urinary retention in subjects undergoing midurethral slings found that phenazopyridine decreased the VT failure rate from 30% to 8% (5). The investigators hypothesize that giving a dose of phenazopyridine the morning after surgery will significantly reduce the rate of postoperative urinary retention in women undergoing prolapse repair.

Enrollment

152 patients

Sex

Female

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Women undergoing overnight admission after prolapse surgery

Exclusion criteria

  • Unable to provide consent
  • Under 18 years of age
  • Pregnant women
  • Prisoners
  • Using intermittent self-catheterization preoperatively
  • Neurological disease or spinal cord injury resulting in voiding dysfunction
  • Undergoing spinal or epidural anesthesia for the procedure
  • Allergy to phenazopyridine
  • Renal insufficiency
  • Liver disease
  • Intra-operative bladder injury necessitating use of prolonged indwelling Foley catheter

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

152 participants in 2 patient groups

Phenazopyridine
Experimental group
Description:
Participant is given Phenazopyridine 200mg on postoperative day 1
Treatment:
Drug: Phenazopyridine
No Phenazopyridine
No Intervention group
Description:
Participant is not given Phenazopyridine on postoperative day 1

Trial documents
1

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems